Stock Taper 
FBIOP
$17.79
▼ DOWN 0.61% (-0.11)
KEY STATISTICS
Market Cap$138.79 M
52w High$21.43
52w Low$6.27
Dividend Yield14.05%
FrequencyMonthly
P/E9.14
Volume2.78K
Shares Out.7.56M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Lindsay Allan Rosenwald
COMPENSATION 2026
Salary$62,665
Stock Awards$2,199,592
Incentive Plan Pay$0
All Other Comp.$125,000
Total$2,887,256
ABOUT
SECTOR
Healthcare
WENT PUBLIC
November 14, 2017
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
78
UPCOMING EARNINGS
DateNov 16, 2026
DayMonday
Rev. Est.$21.57M
NOV
16
MON
PRICE
$17.79 ▼ DOWN 0.61% (−$0.11)About Fortress Biotech, Inc.
https://www.fortressbiotech.com ↗Fortress Biotech, Inc. develops and commercializes dermatology and biopharmaceutical products, including treatments for acne, skin conditions, wounds, cancers, rare diseases, and advanced therapies, with ongoing development of late-stage and precl...
INDUSTRY
Biotechnology
A PRODUCT FORTRESS BIOTECH, INC. IS KNOWN FOR
ZYCUBO® (copper histidinate)
ZYCUBO®, FDA-approved in January 2026, is the first and only treatment for Menkes disease, a rare pediatric genetic disorder, developed by Cyprium Therapeutics, a Fortress Biotech subsidiary.
RATINGS SNAPSHOT
Overall rating: C-
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings3
Price To Book1
Overall Score1
INSIDER TRADES
★
OFFICER: CHIEF FINANCIAL OFFICER
Jin David
Purchase · 400.0K shares
2026-06-22
★
OFFICER: CHIEF FINANCIAL OFFICER
Jin David
Purchase · 3.0K shares
2026-04-01
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: PRESIDENT, CEO & CHAIRMAN
ROSENWALD LINDSAY A MD
Purchase · 475.4K shares
2026-03-18
★
DIRECTOR, OFFICER: EXECUTIVE VICE CHAIRMAN
WEISS MICHAEL S
Purchase · 475.4K shares
2026-03-18
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 IPSC | $1.86 | COMPARE |
 EQ | $1.92 | COMPARE |
 CUE | $37.05 | COMPARE |
 TELO | $1.23 | COMPARE |
 VTVT | $31.80 | COMPARE |
 NRXP | $3.32 | COMPARE |
 GNTA | $0.70 | COMPARE |
 SNTI | $0.32 | COMPARE |